SCHEMBL1962312

SCHEMBL1962312

Cc1cccc(-n2c(C)nc3ccccc3c2=O)c1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.77
▸ SMN1; SMN2 Q16637 4/20 0.73
▸ POLB P06746 3/20 0.70
▸ LMNA P02545 2/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ PLA2G1B P04054 1/20 0.67
▸ HPGD P15428 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.67
▸ ATG4B Q9Y4P1 1/20 0.67
▸ ALDH1A1 P00352 2/20 0.64
▸ ALOX12 P18054 1/20 0.64
▸ ALOX15 P16050 1/20 0.62
▸ TP53 P04637 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ MAPK1 P28482 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30122631 0.88 MAPK1 (0.75) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL1682746 0.88 MAPK1 (0.75) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL30726097 0.87 HSD17B10 (0.75) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL29154650 0.87 HSD17B10 (0.75) HSD17B10SMN1; SMN2POLBLMNAMEN1
SCHEMBL29154635 0.87 HSD17B10 (0.75) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL30726098 0.87 HSD17B10 (0.75) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL30726096 0.87 HSD17B10 (0.75) HSD17B10SMN1; SMN2POLBLMNAMEN1
SCHEMBL29839759 0.86 HSD17B10 (0.73) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL4959092 0.86 HSD17B10 (0.73) HSD17B10SMN1; SMN2POLBLMNAMEN1
SCHEMBL29839760 0.86 HSD17B10 (0.73) HSD17B10SMN1; SMN2POLBLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 — — US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 — — US disclosed
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC (US) 2017-08-10 — — US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 — — US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 — — US disclosed
US-9486455-B2 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2016-11-08 — — US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 — — US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 — — US disclosed
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2014-06-05 — — US disclosed
US-8552009-B2 Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. 2013-10-08 — — US disclosed
US-20100152209-A1 Compounds for Modulating TRPV3 Function HYDRA BIOSCIENCES INC. (US) 2010-06-17 — — US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 — — US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 — — US disclosed
US-20090018147-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES INC. (US) 2009-01-15 — — US disclosed
WO-2008140750-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES INC. (US) 2008-11-20 — — WO disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 — — US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 — — US disclosed
US-20070179164-A1 Compounds for modulating TRPV3 function HYDRA BIOSCIENCES, INC. (US) 2007-08-02 — — US disclosed
WO-2007056124-A2 COMPOUNDS FOR MODULATING TRPV3 FUNCTION HYDRA BIOSCIENCES, INC. (US) 2007-05-18 — — WO disclosed
CN-1708306-A Quinazolinone compounds as calcilytics NPS PHARMA INC (US) 2005-12-14 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155417-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 HSD17B10 2713/4885SMN1; SMN2 2219/4885POLB 4849/4885
US-20090018147-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 HSD17B10 2713/4885SMN1; SMN2 2219/4885POLB 4849/4885
US-20100152209-A1 Compounds for Modulating TRPV3 Function TRPV3, TRPV1, TRPV4 HSD17B10 2713/4885SMN1; SMN2 2219/4885POLB 4849/4885
US-20070179164-A1 Compounds for modulating TRPV3 function TRPV3, TRPV1, TRPV4 HSD17B10 2713/4885SMN1; SMN2 2219/4885POLB 4849/4885
US-20170224687-A1 COMPOUNDS FOR MODULATING TRPV3 FUNCTION TRPV3, TRPV1, TRPV4 HSD17B10 2713/4885SMN1; SMN2 2219/4885POLB 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback